FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.

BMC Cancer 2016 Jan 16;16:24. Epub 2016 Jan 16.

Department of Surgery, Austin Health, University of Melbourne, Heidelberg, VIC, Australia.

Background: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic cancer.

Methods: PAK1 expression was measured in pancreatic cancer specimens by immunohistochemistry and in pancreatic cancer cell lines by western blotting. The effect of inhibition of PAK1 by either shRNA knock-down (KD), or by a selective inhibitor, FRAX597, alone or in combination with gemcitabine, on cell proliferation and migration/invasion was measured by thymidine uptake and Boyden chamber assays, respectively. The effect on tumour growth and survival was assessed in orthotopic murine models.

Results: PAK1 was expressed in all human pancreatic cancer samples tested, an7d was upregulated in all pancreatic cancer cell lines tested. PAK1 KD inhibited pancreatic cancer cell growth and survival, and increased sensitivity to gemcitabine treatment. AKT activity and HIF1α expression were also inhibited. FRAX597 inhibited pancreatic cancer cell proliferation, survival, and migration/invasion. When combined with gemcitabine, FRAX597 synergistically inhibited pancreatic cancer proliferation in vitro and inhibited tumour growth in vivo.

Conclusions: These results implicate PAK1 as a regulator of pancreatic cancer cell growth and survival. Combination of a PAK1 inhibitor such as FRAX597 with cytotoxic chemotherapy deserves further study as a novel therapeutic approach to pancreatic cancer treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2057-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715347PMC
January 2016

Publication Analysis

Top Keywords

pancreatic cancer
44
cancer cell
20
pancreatic
13
growth survival
12
inhibited pancreatic
12
cancer
11
combined gemcitabine
8
cell proliferation
8
inhibitor frax597
8
pak1
8
tumour growth
8
cell lines
8
cell growth
8
pak1 inhibitor
8
cell
6
frax597
5
growth
5
inhibited
5
cancermethods pak1
4
gemcitabine frax597
4

Similar Publications